SynthesisFrontiers in immunology2026
Thyroid dysfunction risk in systemic lupus erythematosus: a systematic review of case-control studies.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated the prevalence of thyroid dysfunction-including clinical and subclinical hyperthyroidism, clinical and subclinical hypothyroidism, and euthyroid sick syndrome (ESS)-and its associated risk factors in patients with systemic lupus erythematosus (SLE) through case-control studies and meta-analysis. Materials and methods: The prevalence of thyroid dysfunction in SLE patients was first examined in two independent cohorts (Luzhou and Enshi). A meta-analysis was subsequently conducted using studies identified from PubMed and other databases to estimate the global prevalence of thyroid dysfunction among SLE patients. Factors associated with thyroid dysfunction in SLE were analyzed within the two cohorts, and meta-analysis was further employed to synthesize evidence on these associations. Results: The prevalence of all thyroid dysfunction subtypes was higher in SLE patients than in healthy controls. Meta-analysis confirmed that, at a global level, SLE patients had a higher prevalence of clinical hypothyroidism, subclinical hyperthyroidism, and ESS compared with healthy controls. Meta-analysis also identified significant associations between clinical hypothyroidism and renal involvement ( Conclusions: Thyroid dysfunction is prevalent among SLE patients worldwide. Severe renal involvement and decreased FT3 levels indicate an increased risk of clinical hypothyroidism in SLE, while reduced FT3 and C3 levels are associated with a higher risk of ESS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.